Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with great optimism in recent weeks about the prospects that insurers will ...

Gilead Sciences (NASDAQ:GILD) saw its stock decline 2.7% in pre-market trading Thursday following news that CVS Health ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...